Nabriva (NASDAQ:NBRV) Therapeuticsplc NBRV has been struggling lately, but the selling pressure may be coming to an end soon. That is because NBRV recently saw a Hammer Chart...
Axsome Therapeutics (NASDAQ:AXSM), Inc. AXSM incurred a loss of 78 cents per share in the fourth quarter of 2020, wider than the Zacks Consensus Estimate of a loss of 73 cents per...
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced that it has completed patient enrollment in the phase III ILLUMINATE-301 study, evaluating tilsotolimod in combination with...
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) incurred an adjusted loss of 35 cents per share in the fourth quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 34...
Amicus Therapeutics (NASDAQ:FOLD) reported a loss of 35 cents per share in the fourth quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 26 cents.Total...
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics plc (NASDAQ:NBRV) . The stock has moved higher by 0.9% in the past month, while it is...
It was a busy week for the sector with updates from quite a few big biotechs. While Celgene (NASDAQ:CELG) won the FDA approval for its bone marrow cancer drug, Gilead’s...
Nabriva Therapeutics plc (NASDAQ:NBRV) announced that the FDA has approved its new drug application (NDA) for both intravenous (IV) and oral formulations of Xenleta (lefamulin)...
Nabriva Therapeutics plc (NASDAQ:NBRV) announced that it plans to resubmit a new drug application (NDA) for Contepo (Fosfomycin) injection to the FDA early in the fourth quarter...
Investors in Nabriva Therapeutics plc (NASDAQ:NBRV) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 16, 2019 $2.50...